Provider Alert! COVID-19 Convalescent Plasma Benefit ModifiedTexas Children's Health Plan
Date: July 5, 2022
Attention: All Providers
Effective Date: December 28, 2021
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: On February 10, 2022, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies for the treatment of COVID-19 patients with immunosuppressive disease or receiving immunosuppressive treatment in either the inpatient or outpatient setting. Convalescent plasma treatment of hospitalized patients with COVID-19 has been subject to EUA since August of 2020. Subsequent scientific studies have indicated the need to modify this EUA by limiting use in immunocompromised patients. A new HCPCS code C9507 was created to describe this service (C9507 long descriptor: Fresh frozen plasma, high titer COVID-19 convalescent, frozen within 8 hours of collection, each unit).
How this impacts providers:
- Effective for dates of service on or after December 28, 2021, procedure code C9507 (administration of high titer COVID-19 convalescent fresh frozen plasma in the outpatient) is a benefit. Procedure code C9507 is applicable for diagnosis code U071.
- Clients of all ages, including pregnant women and children who meet EUA criteria, may be eligible for procedure code C9507.
- Providers must follow the National Institutes of Health COVID-19 Treatment Guidelines for convalescent plasma, which can be found on the following webpage: NIH COVID convalescent plasma guidelines.
- Procedure code C9507 can be administered by the following providers and places of service:
|Place of Service||Provider Type|
|Outpatient Hospital||Ambulatory surgical center|
|Outpatient Hospital||Hospital Providers|
HHSC will cover convalescent plasma as a non-risk payment.
Note: Prior authorization will not be required for procedure code C9507 in fee-for-service
Next steps for providers: Prescribers should share this communication with their staff.
If you have any questions, please email Provider Network Management at: email@example.com.